Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide Combined With Glutamine in Radiation Intestinal Injury
NCT06617182Phase 2Recruiting
- Sponsor
- Yongquan Shi
- Start
- Sep 2024
- Primary completion
- Oct 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in radiation enteritis comparing The thalidomide group, The glutamine group and The thalidomide combined with glutamine group (3 arms). Primary endpoint: Treatment response rate at 8 weeks. Started Sep 2024; status: recruiting.
02
Drugs
thalidomideglutamine
03
Conditions
radiation enteritis
Beyond the preview
Go deeper on NCT06617182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617182.